Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aligos Therapeutics Q2 2024 GAAP EPS $0.03 Beats $(0.16) Estimate, Sales $1.061M Down From $2.592M YoY

Author: Benzinga Newsdesk | August 06, 2024 05:46pm
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.16) by 118.75 percent. The company reported $1.061 million in sales this quarter. This is a 59.07 percent decrease over sales of $2.592 million the same period last year.

Posted In: ALGS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist